Our Work
Latham & Watkins Advises Fractyl Health in its US$100 Million Series F Financing
June 16, 2021
A Boston-based team advises the company pioneering treatments for metabolic diseases.
Fractyl Health, a life sciences company dedicated to developing novel therapeutic interventions aimed at reversing the metabolic disease epidemic, has announced the closing of a US$100 million Series F financing. The financing was led by new investors Maverick Capital, M28 Capital, and Population Health Partners, with participation by other new and existing investors.
Latham & Watkins LLP represents Fractyl Health in the financing with a Boston-based corporate deal team led by partners Hans Brigham, Evan Smith, and Spencer Ricks.